The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow
dc.contributor.author | Pors, Klaus | * |
dc.contributor.author | Goldberg, F.W. | * |
dc.contributor.author | Leamon, C.P. | * |
dc.contributor.author | Rigby, A.C. | * |
dc.contributor.author | Snyder, S.A. | * |
dc.contributor.author | Falconer, Robert A. | * |
dc.date.accessioned | 2016-08-17T14:34:07Z | |
dc.date.available | 2016-08-17T14:34:07Z | |
dc.date.issued | 2009-11 | |
dc.identifier.citation | Pors K, Goldberg FW, Leamon CP et al (2009) The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow. Drug Discovery Today. 14 (21/22): 1045-50. | |
dc.identifier.uri | http://hdl.handle.net/10454/8821 | |
dc.description | No | |
dc.description.abstract | Since the development of the first cytotoxic agents, synthetic organic chemistry has advanced enormously. The synthetic and medicinal chemists of today are at the centre of drug development and are involved in most, if not all, processes of drug discovery. Recent decreases in government funding and reformed educational policies could, however, seriously impact on drug discovery initiatives worldwide. Not only could these changes result in fewer scientific breakthroughs, but they could also negatively affect the training of our next generation of medicinal chemists. | |
dc.language.iso | en | |
dc.subject | Medicinal chemistry | |
dc.subject | Chemical biology | |
dc.subject | Diversity-oriented synthesis | |
dc.subject | EPSRC | |
dc.subject | Government funding | |
dc.subject | NCI | |
dc.subject | Cancer drug discovery | |
dc.title | The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow | |
dc.status.refereed | Yes | |
dc.type | Article | |
dc.type.version | No full-text in the repository | |
dc.identifier.doi | https://doi.org/10.1016/j.drudis.2009.07.004 | |
dc.openaccess.status | closedAccess |